CelLBxHealth plc Stock
Stocks
CLBX
GB0034330679
Advanced Medical Equipment & Technology
OTC Markets Traded|
Market Closed -
London S.E.
00:35:19 14/11/2026 HKT
|
5-day change | 1st Jan Change | ||
| 0.6000 GBX | 0.00% |
|
0.00% | -45.45% |
| 10-22 | CelLBxHealth warns of revenue timing delays amid commercial progress | AN |
| 10-21 | WINNERS & LOSERS: Mobico and Ashtead surge on takeover news | AN |
| Market Cap | 6.82M 9.02M 8.17M 7.56M 12.85M 850M 13.3M 90.78M 36M 454M 33.83M 33.12M 1.44B | P/E 2026 * |
-0.26x | P/E 2027 * | -3.87x |
|---|---|---|---|---|---|
| Enterprise Value | 5.52M 7.3M 6.61M 6.12M 10.4M 688M 10.77M 73.47M 29.13M 368M 27.38M 26.8M 1.17B | EV / Sales 2026 * |
0.37x | EV / Sales 2027 * | 0.43x |
| Free-Float |
95.3% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| CLBX | Delayed | |
OTC Markets
| ANPCF | Delayed | |
|
Deutsche Boerse AG
| DWV | Delayed |
Last Transcript: CelLBxHealth plc
| 16/10/25 | Angle names Peter Collins as interim CEO | AN |
| 28/05/25 | RBC cuts National Grid; Citigroup cuts South32 | AN |
| 23/01/25 | HSBC raises FirstGroup, Goldman cuts Ithaca | AN |
| 14/09/23 | JPMorgan ups Rio Tinto; Redburn likes Carnival | AN |
| 24/01/22 | Berenberg Initiates Angle With Buy Rating, Sets PT | MT |
| 1 month | -29.41% | ||
| 3 months | -56.36% | ||
| 6 months | -46.67% | ||
| Current year | -45.45% |
| 1 week | 0.55 |  | 0.65 |
| 1 month | 0.53 | | 1 |
| Current year | 0.53 | | 2.8 |
| 1 year | 0.53 | | 2.8 |
| 3 years | 0.53 | | 37.4 |
| 5 years | 0.53 | | 163.75 |
| 10 years | 0.53 | | 163.75 |
| Manager | Title | Age | Since |
|---|---|---|---|
Sinéad Armstrong
DFI | Director of Finance/CFO | - | 01/01/1999 |
| Chief Tech/Sci/R&D Officer | - | 01/01/2025 | |
Karen Miller
CTO | Chief Tech/Sci/R&D Officer | - | 05/06/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Jan Groen
CHM | Chairman | 67 | 22/05/2023 |
Klaas de Boer
BRD | Director/Board Member | 61 | 12/01/2026 |
| Director/Board Member | 61 | 12/01/2026 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 19/12/25 | Buy | Chief Executive Officer | 5,000,000 | 1.5497% | ||
| 19/12/25 | Buy | Chief Financial Officer | 2,500,000 | 0.7749% | ||
| 19/12/25 | Buy | Chairman | 5,000,000 | 1.5497% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | 0.00% | -67.57% | -94.06% | 9.02M | |
| +0.11% | +3.44% | +19.08% | +56.15% | 259B | |
| +0.37% | +2.95% | +6.21% | +18.28% | 163B | |
| +0.84% | -5.32% | -22.51% | +59.86% | 152B | |
| +0.32% | -0.67% | -57.42% | -14.00% | 64.07B | |
| +1.28% | +6.28% | +25.20% | +66.87% | 60.84B | |
| +0.34% | -2.33% | -1.94% | -7.69% | 53.91B | |
| +0.55% | +1.27% | +14.81% | +60.38% | 48.78B | |
| -0.29% | -2.76% | +1.54% | +82.66% | 48.96B | |
| -0.42% | +1.58% | +18.81% | +79.84% | 45.43B | |
| Average | +0.31% | +0.28% | -6.38% | +30.83% | 90B | |
| Weighted average by Cap. | +0.36% | +0.60% | +2.15% | +44.64% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 14.93M 19.75M 17.89M 16.55M 28.14M 1.86B 29.13M 199M 78.84M 995M 74.1M 72.53M 3.16B | 25.5M 33.72M 30.56M 28.26M 48.06M 3.18B 49.75M 340M 135M 1.7B 127M 124M 5.39B |
| Net income | -8.6M -11.37M -10.31M -9.53M -16.21M -1.07B -16.78M -115M -45.4M -573M -42.68M -41.77M -1.82B | -2.6M -3.44M -3.12M -2.88M -4.9M -324M -5.07M -34.62M -13.73M -173M -12.9M -12.63M -550M |
| Net Debt | -1.3M -1.72M -1.56M -1.44M -2.45M -162M -2.54M -17.31M -6.86M -86.58M -6.45M -6.31M -275M | 4.06M 5.37M 4.87M 4.5M 7.66M 507M 7.93M 54.09M 21.45M 271M 20.16M 19.73M 859M |
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/11/26 | GBX 0.6000 | 0.00% | 698,644 |
| 12/11/26 | GBX 0.6000 | 0.00% | 791,528 |
| 11/11/26 | GBX 0.6000 | 0.00% | 983,372 |
| 10/11/26 | GBX 0.6000 | 0.00% | 1,505,874 |
| 09/11/26 | GBX 0.6000 | 0.00% | 1,622,053 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Stocks
- CLBX Stock
Select your edition
All financial news and data tailored to specific country editions
